Sesen Bio — Technical Presentation (September 2021)
17 slides from Sesen Bio's technical presentation, Sep 10, 2021
Slide 1: Interim Analysis of Phase I Study of Durvalumab and Vicineum in High-Grade NMIBC
Sandeep Gurram, Sonia Bellfield, Rebecca Dolan, Beatriz Walter, Maria Merino, Scot Niglio, Andrea Apolo, Piyush Agarwal, Vladimir Valera NCT03258593 @SandeepGurramMD Interim Analysis of a Phase I Single-Arm Study of the Combination of Durvalumab and Vicineum (oportuzumab monatox, VB4-845) in Subject
Slide 2: Disclosures
Disclosures • No disclosures to present • Study drugs were provided by Sesen Bio (Vicineum) and AstraZeneca (Durvalumab)
Slide 3: Background
Background • Vicineum is a recombinant fusion protein comprised of an anti-EpCAM linked to a truncated form of Pseudomonas exotoxin A • 98% of BCG-refractory pts with EpCAM overexpression • Phase III VISTA trial has demonstrated efficacy • Duration of response in CR subjects: 287 days • PD-1/PD-L1 i
Slide 4: Vicineum mechanism of action
T cells recognize neoantigen and kill cancer cells T cell proliferation DAMPs Neoantigen releaseVicineum causes immunogenic cell death by triggering damage- associated molecular patterns (DAMPs) Vicineum selectively targets EpCAM on urothelial carcinoma cells Neoantigen presentation and T cell activ
Slide 5: Study Design
Study Design Eligibility Criteria • CIS ± papillary tumor or HG Ta or T1 UC • BCG unresponsive* • Last dose of BCG within 1 year • ECOG PS 0-1 • No prior use of PD-1/PD-L1 inhibitor • No history of upper tract or urethral UC within the last 2 years • Adequate hepatic and renal function Safety Run- i
Slide 6: Baseline Characteristics
Baseline Characteristics Characteristic Vicineum + Durvalumab n = 12 Median age – yr. (range) 69.5 (57 - 82) Sex – no. (%) Male 11 (92) 1 (8) Female Race – no. (%) White, non-Hispanic 12 (100) ECOG performance status – no. (%) 0 10 (83) 2 (17) 1 Smoking History Never Smoker 3 (25) 8 (67) 1 (8) Forme
Slide 7: Baseline Characteristics
Baseline Characteristics Characteristic Vicineum + Durvalumab n = 12 Median age – yr. (range) 69.5 (57 - 82) Sex – no. (%) Male 11 (92) 1 (8) Female Race – no. (%) White, non-Hispanic 12 (100) ECOG performance status – no. (%) 0 10 (83) 2 (17) 1 Smoking History Never Smoker 3 (25) 8 (67) 1 (8) Forme
Slide 8: Baseline Characteristics
Baseline Characteristics Characteristic Vicineum + Durvalumab n = 12 Median age – yr. (range) 69.5 (57 - 82) Sex – no. (%) Male 11 (92) 1 (8) Female Race – no. (%) White, non-Hispanic 12 (100) ECOG performance status – no. (%) 0 10 (83) 2 (17) 1 Smoking History Never Smoker 3 (25) 8 (67) 1 (8) Forme
Slide 9: Baseline Characteristics
Baseline Characteristics Characteristic Vicineum + Durvalumab n = 12 Median age – yr. (range) 69.5 (57 - 82) Sex – no. (%) Male 11 (92) 1 (8) Female Race – no. (%) White, non-Hispanic 12 (100) ECOG performance status – no. (%) 0 10 (83) 2 (17) 1 Smoking History Never Smoker 3 (25) 8 (67) 1 (8) Forme
Slide 10: Primary Outcome
Primary Outcome • Safety cohort: 3+3 design • All 6 subjects enrolled without any DLTs • MTD was determined to be 30 mg Vicineum in 50 mL saline
Slide 11: Tolerability
Tolerability • No dose reductions or discontinuation of any agent • No subjects were taken off study due to treatment related adverse events • Two subjects were taken off study due to unrelated medical issues • Worsening of baseline peripheral vascular disease • Cognitive decline secondary to worsen
Slide 12: Treatment Related Adverse Events
Treatment Related Adverse Events • Number of patients experiencing any TrAE: 12 (100%) • Number of patients experiencing grade ≥3 TrAE*: 3 (25%) • 1 subject required systemic corticosteroids for a persistent grade 2 diarrhea due to checkpoint associated colitis *No grade 4 or 5 TrAE’s were noted Tre
Slide 13: Treatment Related Adverse Events
Treatment Related Adverse Events • Number of patients experiencing any TrAE: 12 (100%) • Number of patients experiencing grade ≥3 TrAE*: 3 (25%) • 1 subject required systemic corticosteroids for a persistent grade 2 diarrhea due to checkpoint associated colitis *No grade 4 or 5 TrAE’s were noted Tre
Slide 14: Secondary Outcomes
Secondary Outcomes • Complete Responses • 3 month: 5/12 (42%) • 12 month: 2/12 (17%) • Two subjects who came off study for unrelated medical reasons were 3- month responders High-grade recurrence No high-grade recurrence Currently on therapy Su bj ec ts
Slide 15: Efficacy Outcomes
Efficacy Outcomes Number of Patients (%) Progression/recurrence of high grade NMIBC 8 (67) Progression to MIBC† 1 (8.3) 12-month cystectomy-free survival 9 (75) Death from bladder cancer 0 (0) † includes at final on-study TUR or occult disease on cystectomy pathology
Slide 16: Conclusions
Conclusions • The combination of Vicineum and Durvalumab in BCG unresponsive NMIBC is tolerated well with no new safety signals • The doublet has a similar safety profile compared to both agents used individually • Interim analysis shows a 3-month CR rate of 42% (5/12) • Further biomarker analysis m
Slide 17: Acknowledgements
Acknowledgements Patients and their Families @SandeepGurramMD Investigators Vladimir Valera Romero MD PhD – PI Sandeep Gurram MD Piyush Agarwal MD Andrea Apolo MD Scot Niglio MD Collaborators Rebecca Dolan PA Sonia Bellfield RN Jacqueline Cadena NP Liang Cao PhD Beatriz Walter MD PhD Maria Merino MD